Table 1.
Characteristics of the analyzed patients with DCM after 5 years
| PARAMETER | Mean ± SD or number of patients (%) |
|---|---|
| Age (years) |
59.0 ± 11.0 |
| Gender (male) |
40 (89) |
| NYHA class | |
| I |
4 (9) |
| II |
22 (49) |
| III |
15 (33) |
| IV |
4 (9) |
| Atrial fibrillation |
15 (33) |
| Hypercholesterolemia |
20 (46) |
| Anemia* |
4 (9) |
| Diabetes mellitus or abnormal glucose level |
9 (20) |
| LV diastolic dysfunction |
4 (9) |
| sPAP >40 mmHg |
4 (9) |
| MR degree | |
| 0 |
7 (15) |
| I |
19 (43) |
| II |
15 (34) |
| III |
4 (9) |
| TR degree | |
| 0 |
23 (51) |
| I |
14 (32) |
| II |
8 (17) |
|
PHARMACOLOGICAL TREATMENT | |
| Loop diuretics |
41 (91) |
| Spironolactone/eplerenone |
39 (87) |
| vBeta-blockers |
40 (88) |
| ACE inhibitors |
41 (91) |
| Sartans (ARBs) |
4 (9) |
| Digoxin |
15 (34) |
| Acenocoumarol/warfarin |
9 (20) |
| Amiodarone |
4 (8) |
| Statins |
22 (49) |
| Insulin |
2 (4) |
| Oral hypoglycemics | 4 (9) |
*Anemia: Hb (g/dL) <13 in men and <12 in women.
ABBREVIATIONS: ACE inhibitors – angiotensin converting enzyme inhibitors; ARB angiotensin receptor blocker; MR mitral regurgitation; NYHA New York heart association; sPAP systolic pulmonary artery pressure; TR tricuspid regurgitation.